Abstract:Haotian Shang, Yanan Chen, Qiulu Wang, Yongliang Yang, Jingyu Zhang Department of Oncology, Clinical College of Second People's Hospital of Lianyungang, Bengbu Medical College, Lianyungang, People's Republic of China Correspondence: Jingyu Zhang, Department of Oncology, Clinical College of Second People's Hospital of Lianyungang, Bengbu Medical College, No. 41, Hailian East Road, Haizhou District, Lianyungang City, Jiangsu Province, People's Republic of China, Email Purpose: This study aimed to investigate the relationship between peripheral blood indices and the efficacy and prognosis of advanced esophageal squamous cell carcinoma (ESCC) patients treated with camrelizumab. Patients and Methods: We retrospectively analyzed 64 patients who received camrelizumab for advanced ESCC at the Second People's Hospital of Lianyungang City between July 2020 and June 2022. The study included examination of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the systemic inflammation index (SII), the lymph-to-monocytes ratio (LMR), the absolute lymphocyte count (ALC), and lactate dehydrogenase (LDH). We used multivariate logistic regression analysis to explore the link existing between peripheral blood and the efficacy of treatment. Determination of potential prognostic factors for Progression-free survival (PFS) and Overall survival (OS) using Cox regression analysis. The nomogram model was developed based on the results of the Cox multivariate analysis. Patients were divided into three groups according to the reduction in LDH and LDL levels before treatment, and the Kaplan-Meier survival curves for the three groups were compared and ROC curves for LDH combined with PLR were plotted. Results: Lower LDH (OR=6.237, 95% CI: 1.625– 23.944) were independently associated with disease control rates(DCR). LDH was independently correlated with PFS (HR: 0.227 95% CI: 0.099– 0.517). LDH and PLR were independently linked to OS. The C index of the nomogram model is 0.819, indicating good predictive performance. Kaplan-Meier Survival Curve suggested better OS in patients with reduced pretreatment LDH and PLR. The area under the ROC curve showed that the LDH index combined with the PLR index predicts patient survival better than the index alone. Conclusion: LDH combined with PLR predicted prognosis in patients with ESCC treated with camrelizumab. Keywords: esophageal squamous cell carcinoma, camrelizumab, immunotherapy, peripheral blood, prognostic index Esophageal cancer (EC) ranks eighth in terms of incidence and sixth in terms of mortality rate worldwide. 1 In contrast to esophageal adenocarcinoma (EAC), esophageal squamous cell carcinoma (ESCC) presents the most common histologic type worldwide. 2 The standard treatment for ESCC is radiation, chemotherapy, or surgery. 3 For patients with advanced EC, combining chemotherapy and immunotherapy provides a longer survival benefit compared to chemotherapy alone. 4 A growing body of data suggests that histologic type is related to the prognosis of esophageal cancer. Programmed death 1 (PD-1) inhibitors can inhibit the programmed death of immune checkpoint proteins, and ESCC was more sensitive to PD-1 inhibitors than EAC. 5 PD-1 inhibitors activate T lymphocytes, which inhibit cancer cell growth and improve overall patient survival. 6 PD-1 inhibitors are safer than chemotherapy and extend patients' overall survival(OS). 7 Camrelizumab is a humanized anti-PD-1 monoclonal antibody. Combining chemotherapy with camrelizumab significantly improved overall and progression-free survival in patients with advanced ESCC compared with chemotherapy and placebo. 8 However, not all patients with ESCC have better efficacy after immunotherapy. Programmed cell death ligand 1 (PD-L1) is currently an effective marker for predicting the efficacy of immunotherapy for EC. PD-L1 combined with Tumor Mutational Burden (TMB) and Tumor Infiltrating Lymphocyte (TIL) could improve the predictive accuracy. However, due to the specific response mechanism of tumor tissues, PD-L1 combined with TMB can predict the efficacy of immunotherapy in most tumor patients, but some patients may still have false negatives. 9 The clinical method of detecting PD-L1 is complex, involving thresholds and antibody selection. PD-L1 measurement involves not only a lack of harmonized standards but also requires complex and expensive laboratory techniques. 10,11 Therefore, we need to find simpler and more convenient markers to predict the efficacy of immunotherapy, so that more patients will benefit. Inflammation has been considered an important factor in tumor development and prognosis. 12 It is well-documented that -Abstract Truncated-

Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib Plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study

Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE

Prognostic Impact of Peripheral Eosinophil Counts in Patients with Diffuse Large B-cell Lymphoma Receiving Chimeric Antigen Receptor T-cell Therapy.

Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular Carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.

Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor

A Correlation Evaluation Between the Peripheral Blood Index and the Prognosis of Advanced Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors.

Impact of Baseline Body Mass Index on the Long-Term Prognosis of Advanced Hepatocellular Carcinoma Treated with Immunotherapy

Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer

The Combination Treatment Strategy of Lenvatinib for Hepatocellular Carcinoma: a Real-World Study

Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study

1001P PD1midKLRG1+Tbethigh Effector Memory T in the Peripheral Blood Correlates with Tumor Response to Combined Therapy with Lenvatinib and Anti-Pd-1 Antibodies in Unresectable Hepatocellular Carcinoma

177P Organ Specific Tumour Response to First-Line (1L) Therapy with Combined Lenvatinib (LEN) and Anti-Pd-1 Antibodies in Patients with Unresectable Hepatocellular Carcinoma (HCC)